---
title: "GLP-1 Indications Continue to Expand: Potential approvals expected through 2026"
date: 2025-08-27T18:57:43.579Z
source: "global.lockton.com"
source_url: https://global.lockton.com/us/en/news-insights/glp-1-indications-continue-to-expand-potential-approvals
---

## Shrnutí (CZ)
ARTICLES / AUGUST 26, 2025

Following other expanded indications (opens a new window) for GLP-1s, Wegovy has now received FDA approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis. This marks a significant expansion in the therapeutic landscape for GLP-1s, highlighting their growing role in addressing complex metabolic conditions. The growing GLP-1 approval pipeline has significant implications for employers in terms of cost, coverage, and employee access.

---

[Otevřít zdroj](https://global.lockton.com/us/en/news-insights/glp-1-indications-continue-to-expand-potential-approvals)
